Literature DB >> 15126356

Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion.

John N Hutchinson1, Jing Jin, Robert D Cardiff, Jim R Woodgett, William J Muller.   

Abstract

Elevated expression of Akt-1 (PKBalpha) has been noted in a significant percentage of primary human breast cancers. Another frequent event in the genesis of human breast cancers is amplification and overexpression of the ErbB-2 receptor tyrosine kinase, an event which is associated with activation of Akt-1. To directly assess the importance of Akt-1 activation in ErbB-2 mammary tumor progression, we interbred separate strains of transgenic mice carrying mouse mammary tumor virus/activated Akt-1 and mouse mammary tumor virus/activated ErbB-2 to derive progeny that coexpress the transgenes in the mammary epithelium. Female transgenic mice coexpressing activated Akt-1 and ErbB-2 develop multifocal mammary tumors with a significantly shorter latency period than mice expressing activated ErbB-2 alone. This dramatic acceleration of mammary tumor progression correlates with enhanced cellular proliferation, elevated Cyclin D1 protein levels, and phosphorylation of retinoblastoma protein. These bitransgenic mammary tumors also exhibit lower levels of invasion into the surrounding tissue and more differentiated phenotypes. Consistent with these observations, female mice coexpressing activated Akt-1 and ErbB-2 developed significantly fewer metastatic lesions than the activated ErbB-2 strain alone. Taken together, these observations suggest that activation of Akt-1 during ErbB-2-induced mammary tumorigenesis may have opposing effects on tumor growth and metastatic progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15126356     DOI: 10.1158/0008-5472.can-03-3465

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  113 in total

Review 1.  Akt isoform-specific signaling in breast cancer: uncovering an anti-migratory role for palladin.

Authors:  Y Rebecca Chin; Alex Toker
Journal:  Cell Adh Migr       Date:  2011-05-01       Impact factor: 3.405

Review 2.  Distinct biological roles for the akt family in mammary tumor progression.

Authors:  Rachelle L Dillon; William J Muller
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

Review 3.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

4.  Akt determines cell fate through inhibition of the PERK-eIF2α phosphorylation pathway.

Authors:  Zineb Mounir; Jothi Latha Krishnamoorthy; Shuo Wang; Barbara Papadopoulou; Shirley Campbell; William J Muller; Maria Hatzoglou; Antonis E Koromilas
Journal:  Sci Signal       Date:  2011-09-27       Impact factor: 8.192

5.  Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.

Authors:  Christopher R Garrett; Domenico Coppola; Robert M Wenham; Christopher L Cubitt; Anthony M Neuger; Timothy J Frost; Richard M Lush; Daniel M Sullivan; Jin Q Cheng; Saïd M Sebti
Journal:  Invest New Drugs       Date:  2010-07-20       Impact factor: 3.850

Review 6.  Signal transduction in transgenic mouse models of human breast cancer--implications for human breast cancer.

Authors:  Richard Marcotte; William J Muller
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-07-24       Impact factor: 2.673

7.  The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration.

Authors:  Y Rebecca Chin; Alex Toker
Journal:  Mol Cell       Date:  2010-05-14       Impact factor: 17.970

Review 8.  AKT/PKB Signaling: Navigating the Network.

Authors:  Brendan D Manning; Alex Toker
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

9.  3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.

Authors:  Matthew Maurer; Tao Su; Lao H Saal; Susan Koujak; Benjamin D Hopkins; Christina R Barkley; Jiaping Wu; Subhadra Nandula; Bhaskar Dutta; Yuli Xie; Y Rebecca Chin; Da-In Kim; Jennifer S Ferris; Sofia K Gruvberger-Saal; Mervi Laakso; Xiaomei Wang; Lorenzo Memeo; Albert Rojtman; Tulio Matos; Jennifer S Yu; Carlos Cordon-Cardo; Jorma Isola; Mary Beth Terry; Alex Toker; Gordon B Mills; Jean J Zhao; Vundavalli V V S Murty; Hanina Hibshoosh; Ramon Parsons
Journal:  Cancer Res       Date:  2009-07-14       Impact factor: 12.701

10.  Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2.

Authors:  Hong Liu; Derek C Radisky; Celeste M Nelson; Hui Zhang; Jimmie E Fata; Richard A Roth; Mina J Bissell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.